Dr Richard Jones is an accomplished life sciences executive with 25 years experience in the pharmaceutical industry both in big pharma, biotech companies, contract organisation and with a strong background across multiple therapy areas. He has broad and extensive experience from business development, strategic alliances, M&As, R&D, early and late stage clinical development, general management and commercialisation. Dr Jones recently was appointed as CEO of BrYet Limited, a privately owned start up biotech company specialising in the field of nanotechnology. Prior to joining BrYet, Dr Jones served as SVP, Head of Europe for Akcea Therapeutics and prior to joining Akcea, served as CEO of Holostem Advanced Therapies, a cell and gene therapy developer/contract development and manufacturing organisation, and Akinion Pharmaceutical AB, where he focused on furthering the company’s clinical program in rare leukemias.

He previously served at Novartis and GSK as VP, Medicines Commercialization Leader Global Haematology at both companies. In these roles, Dr. Jones was responsible for the planning and execution of three global product launches, three regulatory submissions and initiation of several new drug development programs. Earlier at GSK, Dr. Jones served as Vice President, Global Commercial Leader for the company’s Rare Disease Unit, leading the strategy across multiple diseases and platforms. Dr. Jones joined GSK from Genzyme Corporation, where he served as Oncology & Transplant Portfolio Director, Global Oncology business. Prior to Genzyme, Dr. Jones worked as a Managing Consultant with MSI Consultancy and held various International and Therapy Area GM Project lead roles at Shire Plc.

Dr Jones holds a BSc (Hons) in Biochemistry and PhD in Molecular Oncology from University of Surrey.